Cobalis' EU Patent for PreHistin(R) Becomes Effective; Patent Protects Method of Treatment for Cobalis' PreHistin Anti-Allergy Medication.

IRVINE, Calif. -- Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, announced today that its Patent No. 1128835, titled "Cyanocobalamin Treatment in Allergic Disease," has been published by the European Patent Office in the European Patent Bulletin 06/25. With its publication today, the patent is now in effect and protects the method of treatment underlying Cobalis' PreHistin(R) anti-allergy medication.

The European patent represents an important extension of Cobalis' patent portfolio consisting of patents issued in the U.S. and Australia and patents pending in Japan, Canada and Mexico. An estimated 36 million people suffer from seasonal allergies in the European countries of France, Germany, Italy, Spain and the United Kingdom.

PreHistin is a sublingual lozenge containing an allergy-opposing amount of Cyanocobalamin that is absorbed through the buccal membrane, allowing direct introduction into the bloodstream. It is believed that PreHistin may reduce the release of symptom causing histamine and other allergic inflammatory mediators into the body. PreHistin potentially offers an alternative to anti-histamines, which generally are taken after the onset of symptoms and can be sedating or have undesirable side affects.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy prevention medication. Cobalis plans to seek FDA approval to market PreHistin over-the-counter in the US. For further information, visit www.cobalis.com

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our quarterly report on Form 10Q filed with the SEC on February 14, 2006.